Shire sells Daytrana rights back to Noven; Gilead discloses possible FDA warning on plant;

@FiercePharma: Top 10 Generic Drug Companies 2010. Report | Follow @FiercePharma

> Study: Device errors cost $1.1B annually. Report

> Shire is selling the global rights to Daytrana, its patch for attention deficit hyperactivity disorder, back to the treatment's developer and manufacuturer, Noven Pharmaceuticals. News

> New DNA tests aim to detect colon cancer early. Article

> Maintenance and procedural problems at a Gilead Sciences manufacturing and distribution facility could bring a warning letter from the FDA, the company disclosed. Report

> Pfizer won a ruling throwing out a claim by a woman who claims she suffered injuries as a result of taking the anti-epilepsy drug Neurontin. Story

> Alzheimer's biomarkers found in spinal fluid. Report

> Bisphosphonates, a class of medicines widely used to prevent bone loss, don't increase the risk of cancer of the esophagus or stomach, a study found. Article

> Genentech, a member of the Roche Group, got the FDA nod for a longer length of therapy for Valcyte in adult kidney transplant patients at high risk for cytomegalovirus disease. Item

> Some patients with congestive heart failure are not receiving recommended medicines that could keep them alive longer and out of the hospital, a trend that may be adding to the nation's health costs, U.S. researchers say. Report

Biotech News

 @FierceBiotech: Report: China readies $1.5B plan to bolster biotech. Article | Follow @FierceBiotech

 @JohnCFierce: SciClone says the feds are probing China activities; shares plunge 32 percent. News | Follow @JohnCFierce

> Developers zero in on the new 'bio-better' strategy. Report

> Dicerna bags $25M Series B for next-gen RNAi work. News

Medical Device News

> FAA fines Boston Scientific $91K for transport issues. Report

> Boston Sci gets document request from grand jury. Article

Drug Delivery News

> Researchers crack blood-brain barrier to treat tumors. Story

> Metal-packing nanoparticles treat cancer, useful for MRI. Item

> Elan's drug delivery unit takes on innovation. News

And Finally... A recent ruling on an obscure, 20-year-old tax dispute between Ottawa and GlaxoSmithKline is being hailed by tax lawyers as a victory that creates an important precedent for multinational clients in fights with the Canada Revenue Agency. Story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.